Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

Latest Trials

Systemic therapy trial

MoST Addendum 17 : A single arm, open label, signal-seeking, phase II trial of tepotinib in patients with...

This Phase II trial is trying to understand the effect of targeted therapy (tepotinib) in people with advanced non-small cell lung cancer.

Status : Recruiting

Systemic therapy trial

frontMIND : A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the...

This Phase III trial is trying to understand how safe and effective it is to combine targeted therapy (tafasitamab plus lenaliomide) with chemotherapy (R-CHOP) for the treatment of people with diffuse large B-cell lymphoma, compared to using chemotherapy (R-CHOP) alone

Status : Recruiting

Systemic therapy trial

A Phase 1 First In Human Study Evaluating Safety And Efficacy Of ABBV-637 As Either...

This Phase I trial is evaluating how safe and tolerable a new cancer drug (ABBV-637) is alone, or in combination with chemotherapy (docetaxel) or targeted therapy (osimertinib) in in people with relapsed or refractory solid cancers

Status : Recruiting

Systemic therapy trial

A Randomized Phase 3 Study of Tislelizumab in Combination With Sitravatinib in Patients...

This phase III trial will evaluate the combination of two types of targeted therapy to determine if it will be safe and effective to treat people that have been diagnosed with locally advanced or metastatic non-small cell lung cancer that has progressed (got worse) following previous chemotherapy

Status : Recruiting

Systemic therapy trial

RAMPART : An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised...

This phase III trial is trying to assess whether using a single type of immunotherapy or a combination of two types of immunotherapy will improve survival outcomes for people with renal cell carcinoma that has been surgically removed, when compared to current standard-of-care (active monitoring)

Status : Recruiting

Systemic therapy trial

RELATIVITY : A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With...

This phase II trial aims to assess the safety of two types of immunotherapy (nivolumab and relatlimab) in combination with chemotherapy, to determine if it will improve survival outcomes for people with untreated Stage IV or recurrent non-small cell lung cancer, compared to using one type of immunotherapy (nivolumab) and chemotherapy for the treatment of people with this type of cancer

Status : Recruiting

Systemic therapy trial

SunRISe-2 : A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination...

This phase III trial is evaluating the effectiveness of TAR-200, an intravesical drug-delivery system that involves administering treatment into the bladder directly, in combination with a targeted therapy in patients with muscle-invasive urothelial bladder cancer who are not receiving surgery to remove the bladder

Status : Recruiting

Systemic therapy trial

eMonarcHER : eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib...

This Phase III trial is trying to understand how effective a targeted cancer drug (abemaciclib) is in people with early stage HR+/HER2+ breast cancer who are taking hormone therapy after surgery

Status : Recruiting

Systemic therapy trial

CheckMate73L : A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent...

This phase 3 trial is comparing the effectiveness of concurrent chemoradiotherapy (CCRT) followed by different combinations targeted therapies (nivolumab, ipilimumab or durvalumab) for the treatment of locally advanced non-small call lung cancer

Status : Recruiting

Systemic therapy trial

A First-in-Human, Phase 1a/1b, Open Label, Dose-Escalation and Expansion Study to...

This Phase I trial is trying to determine how safe and tolerable a targeted therapy (BGB-3245) is in people with solid cancers with B-RAF genetic mutations.

Status : Recruiting

 

Looking for a trial? Use the search functionality to find the trial you are finding.